Tarlige's four-spec tablet has been approved in Japan for treatment of peripheral neuropathic pain

recently, Daiichi Sankyo, a Japanese pharmaceutical company, announced that 2.5mg, 5mg, 10mg and 15mg tablets of the mirolige (mirogabalin besylate) have been approved in Japan for the treatment of peripheral neuropathic pain (PNP)generally, the initial dose in adult patients is 5 mg, taken orally twice daily, and then gradually increased by 5 mg at least one week's interval until 15 mgThe dose can be adjusted appropriately between 10 mg and 15 mg according to age and symptoms, orally twice dailythe activedrug(http:// of TarligeTarligeingredient is mirogabalin, an alpha2-sepligand ligand created by the first third co-creation, which can be preferentially and selectively combined with voltage-dependent calcium through oral administration Channels (1 and 2) of alpha 2-1 subunits, but significantly more potent than pregabalin, these calcium channels are widely found in all areas of the body to mediate pain transfer and treatment of the neural system, mirogabalin has a unique binding characteristics and long-lasting effectmirogabalin belongs to the drug category known as Gabapentin and Pribarinfirst filed aapplication for Tarlige'snew drug(http:// in February 2018, which was approved based on positive data from a Phase III clinical study conducted in patients with diabetic peripheral neuropathic pain (DPNP) and a Phase III clinical study in patients with post-herpes neuropathic pain (PHN)Both studies were conducted in Asia, including Japanfirst three, Tarlige will provide patients in Japan andmedical(http://health professionals with an innovative treatment for peripheral neuropathic pain (PNP)PNP is caused by peripheral nerve damage or dysfunction caused by a variety of causes, typical PNP includes diabetic PNP (DPNP) and post-herpes nerve pain (PHN)